<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828724</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-015</org_study_id>
    <nct_id>NCT00828724</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State</brief_title>
  <official_title>An Open Label, Single Dose, Cross-Over Study to Assess the Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the PK properties in fed and fasted men and women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic properties of a single oral dose of lorcaserin in the fed versus fasted state</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lorcaserin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin 10mg</intervention_name>
    <arm_group_label>Lorcaserin 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged between 18 and 65 years (inclusive)

          2. Able to give signed informed consent

          3. BMI 27-45 kg/m2, inclusive

          4. Eligible male and female subjects must agree not to participate in a conception
             process.

          5. Considered to be in stable health in the opinion of the Investigator.

        Exclusion Criteria:

          1. Prior participation in any study of lorcaserin.

          2. Clinically significant new illness in the 1 month before screening

          3. Not suitable to participate in the study in the opinion of the Investigator including
             an existing physical or mental condition that prevents compliance with the protocol

          4. History of any of the following cardiovascular conditions:

               -  Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG),
                  CVA, TIA or RIND within 6 months of screening;

               -  Cardiac arrhythmia requiring medical or surgical treatment within 6 months of
                  screening

               -  Unstable angina

               -  History of pulmonary artery hypertension

          5. Positive result of HIV, hepatitis B or hepatitis C screens

          6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell
             carcinoma with clean surgical margins)

          7. Initiation of a new prescription medication within 1 month prior to screening.

          8. Recent history (within 2 years prior to the screening visit) of alcohol or
             drug/solvent abuse or a positive screen for drugs of abuse at screening.

          9. Participated in any clinical study with an investigational drug, biologic, or device
             within 1 month prior to screening

         10. Use of SSRIs,SNRIs, and other medications must meet the washout period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christen Anderson, MD, PhD</last_name>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRI Worldwide</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>January 23, 2009</last_update_submitted>
  <last_update_submitted_qc>January 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christen Anderson, MD, PhD</name_title>
    <organization>Arena Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

